Angiotensin Receptor

Angiotensin Receptor製品

• All (25)
• Angiotensin Receptor阻害剤 (1)
• Angiotensin Receptor活性剤(2)
• Angiotensin Receptor拮抗剤(20)
• Angiotensin Receptor作動薬(1)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S5067	Losartan	Losartan(DuP-753) is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.	Eur J Med Res, 2024, 29(1):109 Proc Natl Acad Sci U S A, 2023, 120(6):e2219199120 Cell Death Discov, 2022, 8(1):134
S1578	Candesartan	Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.	J Immunother Cancer, 2024, 12(11)e009805 Front Pharmacol, 2022, 13:828643 Hypertension, 2021, 77(5):1723-1736
S7098	PD123319	PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.	Cell Res, 2021, 10.1038/s41422-020-00464-8 Int J Biochem Cell Biol, 2020, 121:105703 Neurosci Lett, 2020, 716:134684
S1359	Losartan Potassium	Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.	J Immunother Cancer, 2024, 12(11)e009805 Int J Mol Sci, 2023, 24(4)3564 Drug Deliv Transl Res, 2023, 10.1007/s13346-023-01413-9
S7678	Sacubitril/valsartan (LCZ696)	Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.	J Immunother Cancer, 2024, 12(11)e009805 Ren Fail, 2024, 46(2):2392849 Biomed Pharmacother, 2023, 162:114569
S1738	Telmisartan	Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.	J Immunother Cancer, 2024, 12(11)e009805 Int Immunopharmacol, 2024, 139:112707 Viruses, 2024, 16(10)1559
S1507	Irbesartan	Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.	J Immunother Cancer, 2024, 12(11)e009805 Xenobiotica, 2020, 10.1080/00498254.2020.1745318 Front Physiol, 2019, 10:681
S1894	Valsartan	Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.	J Immunother Cancer, 2024, 12(11)e009805 Arch Toxicol, 2022, 96(4):1065-1074 Int J Mol Sci, 2021, 22(16)8598
S2037	Candesartan Cilexetil	Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.	J Immunother Cancer, 2024, 12(11)e009805 Int J Mol Sci, 2022, 23(20)12326 Sci Rep, 2015, 5:8116
S8695	ML221	ML221 is a potent apelin receptor (APJ) functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. The IC50 values of ML221 are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively.	Nat Commun, 2022, 13(1):4229 Nat Commun, 2022, 13(1):4229 J Mol Cell Cardiol, 2021, S0022-2828(21)00246-7
S4102	Eprosartan Mesylate	Eprosartan(SKF-108566J) is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.	J Immunother Cancer, 2024, 12(11)e009805 Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x bioRxiv, 2020, 10.1101/2020.10.13.337774
S3046	Azilsartan	Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.	J Immunother Cancer, 2024, 12(11)e009805 Front Pharmacol, 2021, 12:774709 bioRxiv, 2020, 10.1101/2020.10.13.337774
S1604	Olmesartan Medoxomil	Olmesartan Medoxomil (CS-866,RNH-6270) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.	J Immunother Cancer, 2024, 12(11)e009805 Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505 Sci Rep, 2015, 5:8116
S6665	Sparsentan (PS-433540, RE-021)	Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.	Front Pharmacol, 2022, 13:964370 Biomedicines, 2021, 10(1)86
E0039	A-779	A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.	Int J Biol Sci, 2023, 19(8):2613-2629 Elife, 2022, 11e72266
S3057	Azilsartan Medoxomil	Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.	J Immunother Cancer, 2024, 12(11)e009805 Acta Pharm Sin B, 2023, 13(2):662-677 Sci Rep, 2015, 5:8116
S5581	Olmesartan	Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.	J Immunother Cancer, 2024, 12(11)e009805 bioRxiv, 2020, 10.1101/2020.10.13.337774
S4975	Fimasartan	Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.	Drug Metab Dispos, 2020, 48(12):1264-1270
E4975New	Angiotensin II human TFA	Angiotensin II human TFA(DRVYIHPF TFA, Ang II TFA) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system that regulates blood pressure by activating AT1Rand AT2R, stimulating sympathetic activity, aldosterone production, and renal actions. It also promotes vascular cell growth, collagen synthesis, fibrosis, and induces apoptosis and capillary formation via a redox-sensitive pathway.
E1015New	Angiotensin II human	Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.
S0326	Olodanrigan (EMA401)	Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
E4616New	Buloxibutid	Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension.
S5980	Losartan Carboxylic Acid (EXP-3174)	Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. Losartan Carboxylic Acid inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.
E4951New	Eprosartan	Eprosartan(Teveten, SK-108566) is a selective, competitive, nonpeptide and orally active antagonist of angiotensin II receptor. Eprosartan binds angiotensin II receptors with IC50 values of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively.
E4616New	Buloxibutid	Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension.
S7678	Sacubitril/valsartan (LCZ696)	Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3.	J Immunother Cancer, 2024, 12(11)e009805 Ren Fail, 2024, 46(2):2392849 Biomed Pharmacother, 2023, 162:114569
E4975New	Angiotensin II human TFA	Angiotensin II human TFA(DRVYIHPF TFA, Ang II TFA) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system that regulates blood pressure by activating AT1Rand AT2R, stimulating sympathetic activity, aldosterone production, and renal actions. It also promotes vascular cell growth, collagen synthesis, fibrosis, and induces apoptosis and capillary formation via a redox-sensitive pathway.
E1015New	Angiotensin II human	Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.
S5067	Losartan	Losartan(DuP-753) is a selective, orally administered, nonpeptide blocker of angiotensin II type 1 (AT1) receptor used to treat high blood pressure, diabetic kidney disease, heart failure, and left ventricular enlargement.	Eur J Med Res, 2024, 29(1):109 Proc Natl Acad Sci U S A, 2023, 120(6):e2219199120 Cell Death Discov, 2022, 8(1):134
S1578	Candesartan	Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.	J Immunother Cancer, 2024, 12(11)e009805 Front Pharmacol, 2022, 13:828643 Hypertension, 2021, 77(5):1723-1736
S7098	PD123319	PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.	Cell Res, 2021, 10.1038/s41422-020-00464-8 Int J Biochem Cell Biol, 2020, 121:105703 Neurosci Lett, 2020, 716:134684
S1359	Losartan Potassium	Losartan Potassium is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.	J Immunother Cancer, 2024, 12(11)e009805 Int J Mol Sci, 2023, 24(4)3564 Drug Deliv Transl Res, 2023, 10.1007/s13346-023-01413-9
S1738	Telmisartan	Telmisartan (BIBR 277) is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.	J Immunother Cancer, 2024, 12(11)e009805 Int Immunopharmacol, 2024, 139:112707 Viruses, 2024, 16(10)1559
S1507	Irbesartan	Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM.	J Immunother Cancer, 2024, 12(11)e009805 Xenobiotica, 2020, 10.1080/00498254.2020.1745318 Front Physiol, 2019, 10:681
S1894	Valsartan	Valsartan (CGP-48933) is a selective angiotensin II receptor antagonist, used to treat high blood pressure and congestive heart failure.	J Immunother Cancer, 2024, 12(11)e009805 Arch Toxicol, 2022, 96(4):1065-1074 Int J Mol Sci, 2021, 22(16)8598
S2037	Candesartan Cilexetil	Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist with IC50 of 0.26 nM, used in the treatment of hypertension.	J Immunother Cancer, 2024, 12(11)e009805 Int J Mol Sci, 2022, 23(20)12326 Sci Rep, 2015, 5:8116
S8695	ML221	ML221 is a potent apelin receptor (APJ) functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. The IC50 values of ML221 are 0.70 and 1.75 μM in a cAMP assay and β-arrestin assay, respectively.	Nat Commun, 2022, 13(1):4229 Nat Commun, 2022, 13(1):4229 J Mol Cell Cardiol, 2021, S0022-2828(21)00246-7
S4102	Eprosartan Mesylate	Eprosartan(SKF-108566J) is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.	J Immunother Cancer, 2024, 12(11)e009805 Eur J Drug Metab Pharmacokinet, 2022, 10.1007/s13318-022-00780-x bioRxiv, 2020, 10.1101/2020.10.13.337774
S3046	Azilsartan	Azilsartan (TAK-536) is an angiotensin II type 1 (AT1) receptor antagonist with IC50 of 2.6 nM.	J Immunother Cancer, 2024, 12(11)e009805 Front Pharmacol, 2021, 12:774709 bioRxiv, 2020, 10.1101/2020.10.13.337774
S1604	Olmesartan Medoxomil	Olmesartan Medoxomil (CS-866,RNH-6270) is a selective angiotensin II type 1 (AT(1)) receptor antagonist, used in the treatment of high blood pressure.	J Immunother Cancer, 2024, 12(11)e009805 Nan Fang Yi Ke Da Xue Xue Bao, 2020, 40(4):499-505 Sci Rep, 2015, 5:8116
S6665	Sparsentan (PS-433540, RE-021)	Sparsentan (PS-433540, RE-021, DARA) is a dual endothelin type A receptor(ETA) and angiotensin II type 1 receptor antagonist.	Front Pharmacol, 2022, 13:964370 Biomedicines, 2021, 10(1)86
E0039	A-779	A-779 is a potent and selective antagonist for Angiotensin-(1–7) (Ang-(1-7)) with an IC50 of 0.3 nM in a radioligand binding assay. A-779 shows no significant affinity for AT1 or AT2 receptors at a concentration of 1 μM.	Int J Biol Sci, 2023, 19(8):2613-2629 Elife, 2022, 11e72266
S3057	Azilsartan Medoxomil	Azilsartan Medoxomil (TAK-491) is a potent angiotensin II type 1 (AT1) receptor antagonist, inhibits the RAAS, with an IC50 of 2.6 nM, exhibits >10,000-fold selectivity over AT2.	J Immunother Cancer, 2024, 12(11)e009805 Acta Pharm Sin B, 2023, 13(2):662-677 Sci Rep, 2015, 5:8116
S5581	Olmesartan	Olmesartan (RNH-6270) is an an angiotensin 2 receptor antagonist with antihypertensive activity.	J Immunother Cancer, 2024, 12(11)e009805 bioRxiv, 2020, 10.1101/2020.10.13.337774
S4975	Fimasartan	Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure.	Drug Metab Dispos, 2020, 48(12):1264-1270
S0326	Olodanrigan (EMA401)	Olodanrigan (EMA401, PD-126055, (S) PD-126055) is a highly selective, orally active, peripherally restricted antagonist of angiotensin II type 2 receptor (AT2R). Olodanrigan (EMA401) analgesic action appears to involve the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
S5980	Losartan Carboxylic Acid (EXP-3174)	Losartan Carboxylic Acid (E-3174, EXP-3174), an active carboxylic acid metabolite of Losartan, is a non-peptide angiotensin II (AT1) receptor antagonist. Losartan Carboxylic Acid inhibits the specific binding of [125I]-angiotensin II to VSMC with IC50 of 1.1 nM.
E4951New	Eprosartan	Eprosartan(Teveten, SK-108566) is a selective, competitive, nonpeptide and orally active antagonist of angiotensin II receptor. Eprosartan binds angiotensin II receptors with IC50 values of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively.
E4616New	Buloxibutid	Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension.
E4975New	Angiotensin II human TFA	Angiotensin II human TFA(DRVYIHPF TFA, Ang II TFA) is a vasoconstrictor and a major bioactive peptide of the renin/angiotensin system that regulates blood pressure by activating AT1Rand AT2R, stimulating sympathetic activity, aldosterone production, and renal actions. It also promotes vascular cell growth, collagen synthesis, fibrosis, and induces apoptosis and capillary formation via a redox-sensitive pathway.
E1015New	Angiotensin II human	Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.
E4616New	Buloxibutid	Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension.
E4951New	Eprosartan	Eprosartan(Teveten, SK-108566) is a selective, competitive, nonpeptide and orally active antagonist of angiotensin II receptor. Eprosartan binds angiotensin II receptors with IC50 values of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively.
E4616New	Buloxibutid	Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension.